Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Ordinary Share $0.00001 par value
Symbol
TBPH on Nasdaq
Shares outstanding
50,588,235
Price per share
$20.24
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
49,572,017
Total reported value
$926,767,252
% of total 13F portfolios
0%
Share change
+1,099,432
Value change
+$23,203,255
Number of holders
164
Price from insider filings
$20.24
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Newtyn Management, LLC 8.5% -12% $87,419,000 -$9,299,003 4,300,000 -9.6% Newtyn Management, LLC 31 Dec 2025
BlackRock, Inc. 6.5% $31,548,036 3,235,696 BlackRock, Inc. 31 Mar 2025

As of 31 Dec 2025, 164 institutional investors reported holding 49,572,017 shares of Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH). This represents 98% of the company’s total 50,588,235 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Madison Avenue Partners, LP 19% 9,511,150 0% 7.6% $177,953,617
Weiss Asset Management LP 15% 7,457,060 0% 2.1% $139,521,593
Newtyn Management, LLC 8.5% 4,300,000 -13% 8.5% $80,453,000
BlackRock, Inc. 8% 4,050,525 -0.45% 0% $75,785,323
Irenic Capital Management LP 5.5% 2,760,948 0% 6.8% $51,657,337
VANGUARD GROUP INC 4.7% 2,367,353 +7% 0% $44,293,175
D. E. Shaw & Co., Inc. 2.5% 1,259,941 +4.2% 0.02% $23,573,496
ACADIAN ASSET MANAGEMENT LLC 2.3% 1,165,959 +7% 0.04% $21,806,000
STATE STREET CORP 2.2% 1,101,892 +4.4% 0% $20,616,399
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.9% 963,257 +33% 0.01% $18,022,538
GEODE CAPITAL MANAGEMENT, LLC 1.9% 938,724 +4.5% 0% $17,566,969
DIMENSIONAL FUND ADVISORS LP 1.7% 858,957 +12% 0% $16,071,946
MORGAN STANLEY 1.6% 803,119 +34% 0% $15,026,357
Oasis Management Co Ltd. 1.4% 727,161 -35% 1.8% $13,605,182
UBS Group AG 1.1% 570,425 +11% 0% $10,672,651
TWO SIGMA INVESTMENTS, LP 1.1% 537,341 +132% 0.01% $10,053,650
Qube Research & Technologies Ltd 0.94% 473,498 +124% 0.01% $8,859,148
MARSHALL WACE, LLP 0.83% 418,629 +17% 0.01% $7,832,548
JPMORGAN CHASE & CO 0.82% 416,408 +95% 0% $7,790,992
Assenagon Asset Management S.A. 0.8% 404,144 -2.5% 0.01% $7,561,534
JANUS HENDERSON GROUP PLC 0.79% 400,496 +215% 0% $7,493,280
TWO SIGMA ADVISERS, LP 0.75% 379,500 +89% 0.01% $7,100,445
TANG CAPITAL MANAGEMENT LLC 0.69% 351,252 +33% 0.32% $6,571,925
Pacer Advisors, Inc. 0.67% 338,958 0.02% $6,341,904
NORTHERN TRUST CORP 0.65% 329,927 -3.3% 0% $6,172,934

Institutional Holders of Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 49,572,017 $926,767,252 +$23,203,255 $18.71 164
2025 Q3 48,375,344 $706,279,654 +$36,991,609 $14.60 159
2025 Q2 46,436,015 $512,193,131 +$17,041,767 $11.03 134
2025 Q1 44,895,013 $400,910,124 +$805,783 $8.93 130
2024 Q4 44,887,720 $422,397,233 -$6,899,094 $9.41 128
2024 Q3 45,764,660 $368,891,703 -$13,728,533 $8.06 118
2024 Q2 47,101,751 $399,477,630 -$8,156,185 $8.48 129
2024 Q1 47,958,440 $430,313,409 -$10,017,643 $8.97 119
2023 Q4 48,815,898 $548,690,907 -$21,251,604 $11.24 116
2023 Q3 50,811,645 $438,505,371 -$20,825,244 $8.63 113
2023 Q2 52,784,275 $546,345,758 -$76,354,796 $10.35 117
2023 Q1 60,151,070 $652,600,279 -$20,647,357 $10.85 112
2022 Q4 62,093,388 $696,433,955 -$41,903,451 $11.22 118
2022 Q3 64,074,481 $649,741,089 +$1,849,322 $10.14 114
2022 Q2 64,209,180 $581,714,921 +$11,702,533 $9.06 106
2022 Q1 62,986,284 $602,166,380 +$31,622,746 $9.56 114
2021 Q4 59,337,727 $655,471,603 -$7,845,717 $11.05 109
2021 Q3 60,653,808 $448,777,384 -$37,107,153 $7.40 111
2021 Q2 60,758,215 $882,854,201 +$106,504,226 $14.52 101
2021 Q1 53,537,579 $1,092,709,410 +$7,301,237 $20.41 104
2020 Q4 53,239,274 $946,045,510 +$17,733,590 $17.77 103
2020 Q3 52,459,569 $775,625,748 -$4,497,125 $14.78 113
2020 Q2 52,961,450 $1,111,646,885 -$95,003,651 $20.99 121
2020 Q1 56,904,286 $1,315,179,943 +$267,872,903 $23.11 102
2019 Q4 44,821,941 $1,159,982,320 -$103,049,474 $25.89 103
2019 Q3 46,191,630 $899,811,276 -$42,270,083 $19.48 87
2019 Q2 48,624,391 $794,038,148 +$6,064,175 $16.33 94
2019 Q1 48,467,789 $1,098,829,213 +$14,666,557 $22.67 98
2018 Q4 47,693,431 $1,220,447,234 -$168,216 $25.59 92
2018 Q3 47,402,456 $1,548,591,468 +$9,259,415 $32.67 90
2018 Q2 47,820,954 $1,084,574,647 +$2,240,117 $22.68 83
2018 Q1 47,702,533 $1,156,766,841 +$19,411,519 $24.25 85
2017 Q4 46,927,458 $1,308,786,945 -$13,545,795 $27.89 79
2017 Q3 47,312,839 $1,619,998,372 +$33,457,548 $34.24 80
2017 Q2 46,303,381 $1,844,748,924 +$47,996,533 $39.84 91
2017 Q1 45,113,403 $1,660,949,113 +$168,197,871 $36.82 90
2016 Q4 43,817,541 $1,396,888,696 +$262,074,543 $31.88 96
2016 Q3 35,300,039 $1,277,832,411 +$76,633,705 $36.24 98
2016 Q2 33,917,613 $769,608,364 +$131,840,765 $22.69 94
2016 Q1 28,150,667 $529,049,830 +$42,674,071 $18.80 77
2015 Q4 25,928,974 $424,968,625 +$85,947,257 $16.39 79
2015 Q3 20,539,324 $225,719,337 -$24,553,140 $10.99 78
2015 Q2 22,422,337 $291,927,279 +$16,321,496 $13.02 84
2015 Q1 20,888,616 $362,467,742 +$7,467,773 $17.35 84
2014 Q4 20,412,218 $304,588,647 -$33,281,851 $14.92 86
2014 Q3 21,271,423 $490,440,514 +$17,057,826 $23.05 86
2014 Q2 20,300,819 $647,804,482 +$647,740,494 $31.88 89
2014 Q1 842 $14,609 $17.35 1